279 related articles for article (PubMed ID: 33209599)
1. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH; Du N; Cheng C; Lin H; Guo J; Lin G; Li M; Jiang T; Shi Z; Cui Y; Jin X; Yao J; Xing Y; Yao M; Wang K; Mok TSK; Liu L
Transl Lung Cancer Res; 2020 Oct; 9(5):1759-1769. PubMed ID: 33209599
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence and Concurrent Pathogenic Mutations of
Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y
Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543
[TBL] [Abstract][Full Text] [Related]
3. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
4. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
[TBL] [Abstract][Full Text] [Related]
5. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
6. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients.
Wang S; Li Q; Ma P; Fang Y; Yu Y; Jiang N; Miao H; Tang Q; Yang Y; Xing S; Chen R; Yi X; Li N
Front Mol Biosci; 2022; 9():831382. PubMed ID: 35359599
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
11. Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.
Zhou S; Zhang D; Li J; Zhao J; Wang G; Zhang Y; Bai Y; Chen D; Wu H
Pathol Oncol Res; 2020 Oct; 26(4):2835-2837. PubMed ID: 32602003
[TBL] [Abstract][Full Text] [Related]
12. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognostic value of the
Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL
Biomark Res; 2020; 8():22. PubMed ID: 32607238
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine for pancreatic cancer: Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease.
Keane F; Chou JF; Walch H; Schoenfeld J; Singhal A; Cowzer D; Harrold E; O'Connor C; Park W; Varghese A; El Dika I; Balogun F; Yu KH; Capanu M; Schultz N; Yaeger R; O'Reilly EM
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38702822
[TBL] [Abstract][Full Text] [Related]
15. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
Jia XL; Chen G
Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
[TBL] [Abstract][Full Text] [Related]
16. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a cohort of metastatic lung cancer patients harboring
Notario L; Cucurull M; Cerdà G; Sanz C; Carcereny E; Muñoz-Mármol A; Hernández A; Domènech M; Morán T; Sánchez-Céspedes M; Costa M; Mate JL; Esteve A; Saigí M
Front Oncol; 2023; 13():1239000. PubMed ID: 37916173
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.
Jacobs F; Cani M; Malapelle U; Novello S; Napoli VM; Bironzo P
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944952
[TBL] [Abstract][Full Text] [Related]
20. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
